{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-203936","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.295676+00:00","generated_at":"2026-05-14T23:52:06.944345+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biodesix Q1 revenue $25.6M (+42% YoY); raises FY 2026 revenue guidance to $108-114M","bullets":["Total revenue $25.6M, +42% YoY; Diagnostic Testing $22.3M (+37%), Development Services $3.3M (+99%).","Test volumes up 29% to 17,800; average revenue per test improved on expanded payer coverage and RCM enhancements.","Gross margin 82% (excl. one-time $0.4M recovery), up 300 bps YoY; net loss $7.8M (improved 30%); Adj. EBITDA loss $4.1M (improved 35%).","FY 2026 revenue guidance raised to $108-114M (from $106-112M), midpoint implies 25% growth; expects continued Adj. EBITDA improvement.","Cash $25.6M, up 35% from Dec 2025; includes $16.8M ATM net proceeds, partially offset by Q1 cash outflows."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-203936","json":"https://secwatch.observer/filing/0001193125-26-203936.json","markdown":"https://secwatch.observer/filing/0001193125-26-203936.md","text":"https://secwatch.observer/filing/0001193125-26-203936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000119312526203936/0001193125-26-203936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000119312526203936/bdsx-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:52:06.944345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04712c4c70b5e4aca64523340a43fae434d3035d","claim":"BIODESIX INC reported the first quarter ended March 31, 2026 results: revenue $25.6 million, net income Net loss of $7.8 million. Guidance raised.","evidence_excerpt":"Biodesix Announces First Quarter 2026 Results and Highlights Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439725/000119312526203936/0001193125-26-203936-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$25.6 million"},{"label":"Net income","value":"Net loss of $7.8 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}